2026 corporate spin‑off moves

In July 2026, Solvay reported that its 2023 spin‑off of the specialty‑chemicals unit Syensqo had allowed the remaining business to concentrate on core materials, improve operating margins and generate strong free‑cash‑flow. The company’s share price, after a post‑split rally, settled into a €24‑€28 range and a dividend yield above 9% was projected for 2026, despite headwinds from U.S. tariffs, weaker demand and currency effects.

A few weeks later, in early August 2026, Solventum announced a separate spin‑off of its health‑information‑systems division, which accounts for about 16% of 2025 sales. The move, driven by activist investor pressure, is intended to let the medical‑technology and software businesses pursue distinct growth strategies. The split was accompanied by an upgraded 2026 organic sales‑growth outlook (2.5‑3%) and a higher adjusted earnings‑per‑share forecast ($7.10‑$7.20). Both companies illustrate a broader trend of firms using spin‑offs in 2026 to sharpen focus, unlock value and bolster financial guidance.